Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronidazole for Microbiome Modification in Pediatric PSC/Overlap Syndrome
NCT03069976Completed
- Start
- Jan 2016
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of metronidazole in Primary Sclerosing Cholangitis (PSC), autoimmune hepatitis (AIH) and overlap syndrome. Primary endpoint: Liver function test at 14 days. Started Jan 2016; status: completed.
02
Drugs
metronidazole
03
Conditions
Primary Sclerosing Cholangitis (PSC)autoimmune hepatitis (AIH)overlap syndrome
Beyond the preview
Go deeper on NCT03069976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069976.